+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hunter Syndrome Treatment Market by Treatment (Enzyme Replacement Therapy, Hematopoietic Stem Cell Transplant), End User (Clinics, Home Healthcare, Hospitals) - Forecast 2024-2030

  • PDF Icon

    Report

  • 194 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5532898
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Hunter Syndrome Treatment Market size was estimated at USD 1.09 billion in 2023, USD 1.17 billion in 2024, and is expected to grow at a CAGR of 8.06% to reach USD 1.87 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Hunter Syndrome Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Hunter Syndrome Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Hunter Syndrome Treatment Market, highlighting leading vendors and their innovative profiles. These include ARMAGEN, INC., AVROBIO, Inc., Bioasis Technologies, Inc., CANbridge Life Sciences Ltd., Clinigen Limited, Denali Therapeutics Inc., GC Biopharma corp., JCR Pharmaceuticals Co., Ltd., RegenxBio Inc., and Sangamo Therapeutics, Inc.

Market Segmentation & Coverage

This research report categorizes the Hunter Syndrome Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment
    • Enzyme Replacement Therapy
    • Hematopoietic Stem Cell Transplant
  • End User
    • Clinics
    • Home Healthcare
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Hunter Syndrome Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Hunter Syndrome Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Hunter Syndrome Treatment Market?
  4. What is the market share of the leading vendors in the Hunter Syndrome Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Hunter Syndrome Treatment Market?

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hunter Syndrome Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing government initiatives and awareness pertinent to Hunter syndrome
5.1.1.2. Availability and launch of novel therapies coupled with robust pipelines
5.1.1.3. Growing healthcare expenditure among the population
5.1.2. Restraints
5.1.2.1. Relatively high cost of the treatment
5.1.3. Opportunities
5.1.3.1. Technological advancement in the introduction of treatments such as stem cell therapy
5.1.3.2. Robust pharmaceutical development in competitive drugs
5.1.4. Challenges
5.1.4.1. Lack of skilled professionals in the field
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Hunter Syndrome Treatment Market, by Treatment
6.1. Introduction
6.2. Enzyme Replacement Therapy
6.3. Hematopoietic Stem Cell Transplant
7. Hunter Syndrome Treatment Market, by End User
7.1. Introduction
7.2. Clinics
7.3. Home Healthcare
7.4. Hospitals
8. Americas Hunter Syndrome Treatment Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Hunter Syndrome Treatment Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Hunter Syndrome Treatment Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. ARMAGEN, INC.
12.1.2. AVROBIO, Inc.
12.1.3. Bioasis Technologies, Inc.
12.1.4. CANbridge Life Sciences Ltd.
12.1.5. Clinigen Limited
12.1.6. Denali Therapeutics Inc.
12.1.7. GC Biopharma corp.
12.1.8. JCR Pharmaceuticals Co., Ltd.
12.1.9. RegenxBio Inc.
12.1.10. Sangamo Therapeutics, Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. HUNTER SYNDROME TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. HUNTER SYNDROME TREATMENT MARKET SIZE, 2022 VS 2030
FIGURE 3. HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. HUNTER SYNDROME TREATMENT MARKET DYNAMICS
FIGURE 7. HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 8. HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 10. HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 12. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 14. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 20. HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. HUNTER SYNDROME TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. HUNTER SYNDROME TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUNTER SYNDROME TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 6. HUNTER SYNDROME TREATMENT MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HUNTER SYNDROME TREATMENT MARKET SIZE, BY HEMATOPOIETIC STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 9. HUNTER SYNDROME TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HUNTER SYNDROME TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 13. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 14. AMERICAS HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 15. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 16. ARGENTINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 17. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 18. BRAZIL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 19. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 20. CANADA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 21. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 22. MEXICO HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 23. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 24. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. UNITED STATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 26. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 27. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. ASIA-PACIFIC HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. AUSTRALIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 30. AUSTRALIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. CHINA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. INDIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 34. INDIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 35. INDONESIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 36. INDONESIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. JAPAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 38. JAPAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. MALAYSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 40. MALAYSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. PHILIPPINES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 42. PHILIPPINES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. SINGAPORE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. SINGAPORE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. SOUTH KOREA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 47. TAIWAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 48. TAIWAN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. THAILAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 50. THAILAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. VIETNAM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 52. VIETNAM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 56. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 57. DENMARK HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. EGYPT HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 61. FINLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 63. FRANCE HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. GERMANY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 67. ISRAEL HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 69. ITALY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 70. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. NETHERLANDS HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. NIGERIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 75. NORWAY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 77. POLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 79. QATAR HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. RUSSIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 86. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 87. SPAIN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 89. SWEDEN HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. SWITZERLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. SWITZERLAND HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 93. TURKEY HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 95. UNITED ARAB EMIRATES HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM HUNTER SYNDROME TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. HUNTER SYNDROME TREATMENT MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 99. HUNTER SYNDROME TREATMENT MARKET SHARE, BY KEY PLAYER, 2022
TABLE 100. HUNTER SYNDROME TREATMENT MARKET LICENSE & PRICING

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ARMAGEN, INC.
  • AVROBIO, Inc.
  • Bioasis Technologies, Inc.
  • CANbridge Life Sciences Ltd.
  • Clinigen Limited
  • Denali Therapeutics Inc.
  • GC Biopharma corp.
  • JCR Pharmaceuticals Co., Ltd.
  • RegenxBio Inc.
  • Sangamo Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.17 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.87 Billion
Compound Annual Growth Rate8.0%
Regions CoveredGlobal

Related Topics

Related Reports

Hunter Syndrome Treatment - Global Strategic Business Report - Product Image

Hunter Syndrome Treatment - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Global Hunter Syndrome Treatment Market Analysis & Forecast to 2024-2034 - Product Image

Global Hunter Syndrome Treatment Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Hunter Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 180 Pages
  • Global
From
Mucopolysaccharidosis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Mucopolysaccharidosis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Mucopolysaccharidosis III - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Mucopolysaccharidosis III - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Mucopolysaccharidosis Drug Market

Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the deficiency of lysosomal enzymes. These enzymes are responsible for breaking down complex sugars called glycosaminoglycans (GAGs). Without these enzymes, GAGs accumulate in the body, leading to a wide range of symptoms, including skeletal deformities, organ enlargement, and cognitive impairment. Treatment for MPS is focused on managing symptoms and preventing further progression of the disease. Immune disorders drugs are used to treat MPS, including enzyme replacement therapy (ERT), substrate reduction therapy (SRT), and gene therapy. ERT involves the administration of a recombinant enzyme to replace the missing enzyme, while SRT works by reducing the production of GAGs. Gene therapy is a newer approach that involves the introduction of a healthy gene into the patient's cells to replace the defective gene. Companies in the MPS drug market include Sanofi, Shire, Pfizer, and Ultragenyx Pharmaceuticals. Sanofi is a French pharmaceutical company that produces Aldurazyme, an ERT drug for MPS I. Shire is a biopharmaceutical company that produces Elaprase, an ERT drug for MPS II. Pfizer is an American pharmaceutical company that produces Vimizim, an ERT drug for MPS IV. Ultragenyx Pharmaceuticals is a biopharmaceutical company that produces Mep Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.